Tempus AI (TEM) Stock Drops 9% After $1.5 Billion Personalis Acquisition

TLDR

• Tempus AI is acquiring cancer testing company Personalis for $1.5 billion, or $16.25 per share
• TEM stock dropped 8.8% to $47.81 on Monday, falling below its 50-day moving average of $51.40
• Personalis stock also fell 9.4% to $13.90, despite the deal offering a 5.6% premium to Friday’s close
• Tempus already holds a 12.5% stake in Personalis and expects the deal to close by end of 2026 or early 2027
• Analyst consensus sits at “Hold” with an average price target of $68.92; insiders have sold over $31 million in stock this past quarter

---

Tempus AI announced Monday it will acquire Personalis in an all-cash deal valued at $1.5 billion. The offer price of $16.25 per share represents a 5.6% premium to Personalis’ Friday closing price of $15.39.

Tempus AI, Inc., TEM

Wall Street didn’t cheer. TEM stock fell 8.8% to $47.81, while Personalis dropped 9.4% to $13.90. Both stocks moved sharply lower on heavy volume.

The sell-off pushed TEM below its 50-day moving average of $51.40 — a level traders watch closely. The stock is now down 18% in 2026 and is on track for its fourth straight losing session.

Tempus AI $TEM to ACQUIRE Personalis $PSNL for $1.5 billion, expanding deeper into cancer recurrence monitoring

Personalis shareholders will receive $16.25 per share, a 6% premium to the latest close and a 28% premium to the unaffected 30-day average.

The deal brings…

— Wall St Engine (@wallstengine) July 20, 2026

Tempus said the deal would strengthen its ability to support cancer patients from initial diagnosis through treatment, monitoring, and recurrence detection. Tempus already owns a 12.5% stake in Personalis, so this move consolidates that relationship into a full buyout.

Personalis CEO Chris Hall called the deal the best outcome for shareholders. “After conducting an exhaustive process, we are confident Tempus’ offer provides the most value to our shareholders and the fastest path to bringing Personalis’ industry-leading tests to patients suffering from cancer,” Hall said.

Tempus expects to close the acquisition by the end of 2026 or in early 2027.

Analyst Sentiment Mixed

Despite the drop, not everyone is bearish on TEM. BTIG Research holds a buy rating with an $80 price target. TD Cowen also rates the stock a buy. However, Jefferies has an underperform rating with a $35 target, and Wall Street Zen recently downgraded the stock to sell.

Overall, nine analysts rate TEM a buy, four have a hold, and two have issued sell ratings. The consensus is “Hold” with an average target price of $68.92 — still well above current levels.

Tempus’ most recent quarter came in ahead of estimates. The company posted EPS of -$0.13, beating the -$0.21 consensus. Revenue came in at $348.12 million, slightly above the $345.44 million expected, and up 36.1% year over year.

The company remains unprofitable, with a negative net margin of 22.2% and a negative return on equity of 53.83%. Analysts expect full-year EPS of -$1.35.

Insider Selling Raises Eyebrows

Insider activity has been a talking point. CEO Ryan Fukushima sold 33,284 shares on July 8 at $57.39 each, a transaction worth roughly $1.9 million. CFO James Rogers sold 11,529 shares on June 25 at $55.00. Both trades were made under pre-arranged Rule 10b5-1 plans.

In total, insiders sold over 616,000 shares worth nearly $31.75 million in the last quarter. Corporate insiders currently hold 24.26% of the company.

On the institutional side, Invesco raised its stake by nearly 2,927% in Q2, adding over 204,000 shares. Cathie Wood’s ARK Invest has also been buying into the dip.

TEM last traded at $47.81, with a market cap of $8.57 billion.